Illumina will provide clinical sequencing services to Florida State University’s new Diagnostic Lab for Pediatric Rare Diseases, aiming to accelerate rare disease diagnostics for an estimated 30 million affected Americans.
The mRNA-based test aims to provide objective data to help clinicians distinguish between psychiatric conditions that often share symptoms.
Foundation Medicine will acquire SAGA Diagnostics’ Pathlight MRD platform, expanding its cancer monitoring portfolio. The $595 million deal is expected to close by Q3 2026, with integration supporting treatment selection and recurrence monitoring.
Seegene unveiled its STAgora real-time data analytics platform and an updated CURECA automated PCR system at ESCMID Global 2026, aiming to enhance infectious disease monitoring through integrated laboratory workflows and aggregated test data.
Read More
The cloud-based system aims to address the bottleneck of translating raw genomic data into actionable information for clinical laboratories.
Read More
The $100 million deal brings an ultra-fast system for respiratory viruses to QuidelOrtho’s point-of-care portfolio.
Read More
The Idylla CDx MSI Test detects microsatellite instability in colorectal cancer tissue in under three hours, supporting therapy selection for eligible patients.
Read More
CellCarta has secured exclusive global rights to deploy Biofidelity’s Aspyre Lung assay in lung cancer clinical trials, streamlining genomic testing for trial sponsors and reducing reliance on multiple vendors.
Read More
A $4 million financing round will support development of a liquid specimen biorepository and expand biopsy catchment pilot programs at medical institutions across the US.
Read More
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
Read More
Presentations at the upcoming annual meeting will focus on AI-based analysis, biomarker prevalence, and therapy development.
Read More
The recommendations focus on using next-generation sequencing to evaluate off-target editing risks and chromosomal integrity.
Read More
Biodesix will present seven abstracts—including two oral sessions—at AACR 2026, highlighting advances in automated myeloid testing, liquid biopsy, and NGS-based cancer monitoring platforms.
Read More
A peer-reviewed study suggests molecular signatures can be identified without invasive uterine sampling using whole-transcriptome sequencing and machine learning.
Read More
The BiliSeq molecular test detected bile duct cancer in 82% of cases—compared to 44% with standard pathology—according to a six-year, multi-institutional study.
Read More
The companion diagnostic can now help identify patients with esophageal or gastroesophageal junction carcinoma who may be eligible for pembrolizumab treatment.
Read More
A retrospective study in Lymphatics reports that CSF liquid biopsy testing delivered clinical impact in 82% of CNS lymphoma cases, resolving diagnoses and informing treatment when standard methods were inconclusive.
Read More
New additions to the COMET suite aim to improve flexibility and sensitivity in multiplex tissue analysis for research and preclinical development.
Read More